SYRE — Spyre Therapeutics Balance Sheet
0.000.00%
- $910.76m
- $454.10m
- 38
- 19
- 31
- 19
Annual balance sheet for Spyre Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 146 | 93.1 | 55.7 | 339 | 603 |
Net Total Receivables | — | 0.815 | 0.375 | 0 | — |
Prepaid Expenses | |||||
Total Current Assets | 150 | 98.9 | 62.3 | 342 | 608 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 9.94 | 9.15 | 7.25 | 0 | — |
Other Long Term Assets | |||||
Total Assets | 162 | 110 | 71.1 | 342 | 608 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 16.4 | 20.1 | 14.7 | 32 | 54.1 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 21.8 | 26 | 20.8 | 73.3 | 90.7 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 140 | 83.9 | 50.3 | 269 | 518 |
Total Liabilities & Shareholders' Equity | 162 | 110 | 71.1 | 342 | 608 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |